Navigation Links
VentriNova, Inc. to present at TEDMED 2013
Date:4/16/2013

NEW YORK, April 16, 2013 /PRNewswire/ -- VentriNova, a cardiac regenerative medicine biotechnology company, announced today that Dr. Hina Chaudhry , Founder, will be presenting VentriNova at the TEDMED 2013 conference April 16-19, 2013 as part of the TEDMED Hive for the most innovative startup companies in healthcare.  The meeting takes place at the John F. Kennedy Center for the Performing Arts in Washington, D.C., and it will also be available online at www.TEDMED.com.

Dr. Chaudhry has been named a TEDMED Innovation Scholar and will present VentriNova's vision for cardiac regeneration based on the modulation of the heart's intrinsic repair pathways that lie dormant after birth in humans.  The presentation will include details of the company's compelling pre-clinical data in small and large animal models as well as its translational strategy towards developing clinical therapies and preparing for a human clinical trial.  Corporate growth and financing plans will also be discussed.

"The Hive provides an exciting opportunity to spread the word about innovations that can truly make a difference in healthcare, and I am honored that VentriNova was selected to participate in the program's inaugural event," said Dr. Chaudhry. "I am looking forward to sharing the results of many years of research demonstrating that modulation of the cyclin A2 gene, which is normally silenced in mammalian hearts after birth, has been proven to stimulate growth of new heart muscle cells."

About TEDMED and The Hive

TEDMED is a multi-disciplinary community of innovators and leaders who share a common determination to create a better future in health and medicine. Once a year at The Kennedy Center in Washington, DC, TEDMED curates an unusual and provocative program on the Opera House stage. At TEDMED 2013, 50 transformative innovations and the entrepreneurs, from varied fields both inside and outside health and medicine, that represent them will be part of "The Hive" in association with the Startup Health Network. At The Hive, incubators and accelerators, government-run programs, academic specialists, independent start-ups and labs run by Fortune 500 companies will come together to share and to discover important drivers of innovation.

About VentriNova, Inc.

VentriNova is a preclinical stage regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. No technology on the market or in clinical development, including stem cell-based technologies and other regenerative medicine applications, has the ability to grow new heart muscle cells in the diseased heart.  VentriNova's pioneering science and technology is centered on development of biologic and small molecule regulators of the cyclin A2 gene – the key switch mediating heart cell division.  VentriNova's technology has demonstrated that modulation of the cyclin A2 gene stimulates endogenous growth of new myocytes (heart muscle cells) and significantly enhances cardiac contractile function in both small and large animals.  Led by a world-class team, VentriNova is privately held and backed by Broadview Ventures and NIH funding.  For more information, please visit www.ventrinovainc.com.

Media and Investor Contact:
Michelle Linn
Linnden Communications
Phone: 774-696-3803
Email: michelle@linndencom.com

 

 

 


'/>"/>
SOURCE VentriNova, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
4. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
5. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
6. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
7. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
8. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
9. PRA Expert to Present at Pharmacovigilance Conference
10. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
11. Verenium to Present at Baird Clean Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 2016 , ... Leading CEOs from biotech, pharmaceutical, and healthcare ... 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference is ... access to key decision makers who influence deal making and investment. Attendees gain ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... , the sensor and data driven conferences, will take place on June 7-8, 2016, at the ... UnitedHealth's Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and ...
(Date:5/3/2016)... ... 03, 2016 , ... According to world renowned prostate cancer surgeon, Dr. ... traditionally had two main treatment options: surgery or radiation. Based on a patient’s goals, ... technology has enabled doctors to administer higher doses of radiation to prostate ...
(Date:5/2/2016)... ... 02, 2016 , ... Meister Media Worldwide launches its new ... added functionality give the agricultural world a taste of Meister Media Worldwide’s full ... – from precision farming via satellites and Unmanned Aerial Vehicles (UAVs) to indoor ...
Breaking Biology Technology:
(Date:3/10/2016)... March 10, 2016 --> ... research report "Identity and Access Management Market by Component ... and Governance), by Organization Size, by Deployment, by Vertical, ... by MarketsandMarkets, The market is estimated to grow from ... by 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:3/9/2016)... March 9, 2016  Crossmatch ® , a ... solutions, today announced the addition of smart features ... multi-factor authentication platform. New contextual and application-specific ... step-up security where it,s needed most — while ... DC . --> Washington, ...
(Date:3/3/2016)... and DE SOTO, Kansas ... U.S.-based Stroke Detection Plus® to offer Oncimmune,s Early ... assessment and early detection of lung cancer ... employers, unions and individuals. --> Early CDT®-Lung ... and individuals. --> Oncimmune, a leader in ...
Breaking Biology News(10 mins):